Saltar al contenido
Merck

SML2281

Sigma-Aldrich

BAY 60-2770

≥98% (HPLC)

Sinónimos:

4-[((4-Carboxy-butyl)-{2-[5-fluoro-2-(4′-trifluoromethyl-biphenyl-4-ylmethoxy)-phenyl]-ethyl}-amino)-methyl]-benzoic acid, 4-[[(4-Carboxybutyl)[2-[5-fluoro-2-[[4′-(trifluoromethyl)[1,1′-biphenyl]-4-yl]methoxy]phenyl]ethyl]amino]methyl]benzoic acid

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C35H33F4NO5
Número de CAS:
Peso molecular:
623.63
Código UNSPSC:
12352200
NACRES:
NA.77

Ensayo

≥98% (HPLC)

Formulario

powder

color

white to beige

solubilidad

DMSO: 2 mg/mL, clear

temp. de almacenamiento

2-8°C

cadena SMILES

FC1=CC=C(OCC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(CCN(CC4=CC=C(C(O)=O)C=C4)CCCCC(O)=O)=C1

InChI

1S/C35H33F4NO5/c36-31-16-17-32(45-23-25-6-8-26(9-7-25)27-12-14-30(15-13-27)35(37,38)39)29(21-31)18-20-40(19-2-1-3-33(41)42)22-24-4-10-28(11-5-24)34(43)44/h4-17,21H,1-3,18-20,22-23H2,(H,41,42)(H,43,44)

Clave InChI

CRQMDXFUKDWARU-UHFFFAOYSA-N

Acciones bioquímicas o fisiológicas

BAY 60-2770 is a potent and selective soluble guanylyl cyclase (sGC) heme-independent activator that protects sGC from heme oxidation in smooth muscle tissues. BAY 60-2770 provides cardioprotection and limits the infarct size in rat ischaemia-reperfusion model. Also BAY 60-2770 Ameliorates of urethra dysfunction in high-fat fed obese mice.
Structurally, BAY 60-2770 comprises fluoro and trifluoromethyl moieties. It stimulates in vitro expressed α2/β1 isoform of nitric oxide sensitive guanylyl cyclase (NOsGC). BAY 60-2770 is reported to be effective in treating liver fibrosis and in lowering arterial pressures (both pulmonary and systemic) in animal studies. It elicits anti-aggregating and anti-adhesive effects on platelets and may have therapeutic potential to treat atherothrombotic events.
potent and selective soluble guanylyl cyclase (sGC) heme-independent activator

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Vijay Kumar et al.
Biochemistry, 52(20), 3601-3608 (2013-04-26)
The soluble guanylyl cyclase (sGC) is an important receptor for nitric oxide (NO). Nitric oxide activates sGC several hundred fold to generate cGMP from GTP. Because of sGC's salutary roles in cardiovascular physiology, it has received substantial attention as a
Eduardo C Alexandre et al.
The Journal of pharmacology and experimental therapeutics, 349(1), 2-9 (2014-01-15)
Obesity has emerged as a major contributing risk factor for overactive bladder (OAB), but no study examined urethral smooth muscle (USM) dysfunction as a predisposing factor to obesity-induced OAB. This study investigated the USM relaxant machinery in obese mice and
Camila B Mendes-Silverio et al.
PloS one, 7(11), e47223-e47223 (2012-11-13)
Nitric oxide-independent soluble guanylyl cyclase (sGC) activators reactivate the haem-oxidized enzyme in vascular diseases. This study was undertaken to investigate the anti-platelet mechanisms of the haem-independent sGC activator BAY 60-2770 in human washed platelets. The hypothesis that sGC oxidation potentiates
Anne Sömmer et al.
Biochemical pharmacology, 147, 10-20 (2017-11-21)
Nitric oxide sensitive guanylyl cyclase (NOsGC), a hemoprotein and the major physiological receptor for nitric oxide (NO), is a heterodimer with the α1/β1 and α2/β1 isoforms known to be important for NO-signaling and conversion of GTP to cGMP in humans.
Alexander Kollau et al.
Molecular pharmacology, 93(2), 73-78 (2017-11-16)
Belonging to the class of so-called soluble guanylate cyclase (sGC) activators, cinaciguat and BAY 60-2770 are interesting therapeutic tools for the treatment of various cardiovascular pathologies. The drugs are supposed to preferentially stimulate oxidized or heme-depleted, but not native sGC.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico